A Comparison between Three Graft Manipulation Methods for Haploidentical Stem Cell Transplantation in Pediatric Patients: Preliminary Results of a Pilot Study

Transplantation of hematopoietic stem cells from mismatched related donors makes a potential donor available for every child in need of stem cell transplantation. Here, we compare three different graft manipulation methods in patients with leukemias and lymphomas: positive selection of stem cells with either CD34 (n = 39) or CD133-coated magnetic microbeads (n = 14) and a new strategy which depletes T- and B-cells through the use of CD3- and CD19-coated microbeads (n = 11). Median purity of stem cells was comparable after CD34 (+)-selection and CD133 (+)-selection, whereas stem cells were only slightly enriched after CD3 (+)/CD19 (+)-depletion (97.5 %, 93.4 % and 1.02 %). Indirect depletion of T-cells by positive selection resulted in 1 x 10 (4) (median) residual CD3 (+)-cells/kg (0.7-3 x 10 (4)). Patients with CD3/CD19-depleted grafts received 3.2 x 10 (4) (median) (0.7-16 x 10 (4)) residual T-cells/kg. Those grafts also comprised NK-cells (median number: 86 x 10 (6)/kg), dendritic cells and monocytes/granulocytes. Primary engraftment of the stem cell products was comparable after CD34- and CD133-selection (85 and 72 %). In the CD3/CD19 group, 91 % had a primary engraftment. After reconditioning, all patients (64/64) were finally engrafted. Patients with CD34-selected or CD133-selected grafts had similar incidences of a GvHD II-IV (3 and 7 %), whereas a GvHD was slightly increased in patients receiving CD3/CD19-depleted cells (27 %). Reconstitution of CD3 (+) T-cells was faster in the CD3/CD19 group than in the CD34 or CD133 group. These preliminary results indicate, that CD3/CD19-selected grafts may be advantageous regarding engraftment and immunoreconstitution. Since effector cell with potential antileukemic activity are cotransfused, such grafts may be suited in particular for patients with insufficient remission.

[1]  T. Klingebiel,et al.  Long-term outcome after haploidentical stem cell transplantation in children. , 2004, Blood cells, molecules & diseases.

[2]  P. Wernet,et al.  Transplantation of Haematopoietic Stem Cells Derived from Cord Blood, Bone Marrow or Peripheral Blood: A Single Centre Matched-Pair Analysis in a Heterogeneous Risk Population , 2004, Klinische Padiatrie.

[3]  A. Schulz,et al.  Immune reconstitution in congenital disorders after HLA-haploidentical hemopoietic stem cell transplantation. , 2004, Blood cells, molecules & diseases.

[4]  C. Peters,et al.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses and Leukodystrophies , 2004, Klinische Padiatrie.

[5]  H. Einsele,et al.  Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors , 2004, British journal of haematology.

[6]  G. Henze,et al.  Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. , 2003, Blood.

[7]  T. Klingebiel,et al.  Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. , 2003, Blood.

[8]  N. Sacchi,et al.  Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors , 2002, Leukemia.

[9]  D. Wall,et al.  Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 2002, Blood.

[10]  M. Martelli,et al.  Haploidentical stem cell transplantation in leukemia. , 2001, Blood reviews.

[11]  T. Klingebiel,et al.  Megadose transplantation of purified peripheral blood CD34+progenitor cells from HLA-mismatched parental donors in children , 2001, Bone Marrow Transplantation.

[12]  M. Martelli,et al.  Mismatched T cell-depleted hematopoietic stem cell transplantation for children with high-risk acute leukemia. , 1998, Bone marrow transplantation.

[13]  R. Handgretinger,et al.  A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. , 2004, Cytotherapy.

[14]  T. Klingebiel,et al.  Transplantation of highly purified peripheral-blood CD34+ progenitor cells from related and unrelated donors in children with nonmalignant diseases , 2004, Bone Marrow Transplantation.